Alkermes Plc Stock Price, News & Analysis

Alkermes has released an animation that explores how alcohol dependence impacts the brain, aligning with the conclusion of Dry January. The initiative aims to raise awareness about alcohol-related issues and includes a questionnaire designed to help individuals assess their drinking habits. For those interested, additional multimedia content and ESG storytelling are available through Alkermes' profile on 3blmedia.com. This educational effort reflects Alkermes' commitment to addressing alcohol dependence and supporting individuals seeking help.

Alkermes plc (NASDAQ: ALKS) announced that its investigational immunotherapy, nemvaleukin alfa, has received an Innovation Passport from the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for treating mucosal melanoma. This designation facilitates accelerated market access and provides benefits such as a 150-day assessment for Marketing Authorization Applications (MAA). Previously, nemvaleukin received Orphan Drug and Fast Track designations from the U.S. FDA. The ILAP program, launched in January 2021, aims to speed up access to essential medicines for serious health conditions.

Alkermes plc (Nasdaq: ALKS) will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 11:15 a.m. PST. CEO Richard Pops will host the presentation, which includes a question and answer session. The event can be accessed through the Investors tab on www.alkermes.com and will be archived for 14 days. Alkermes is a global biopharmaceutical company focusing on neuroscience and oncology, with various commercial products targeting alcohol and opioid dependence, schizophrenia, and bipolar I disorder.

Alkermes plc (Nasdaq: ALKS) announced its participation in a fireside chat at the BofA Securities 2022 Biotech SMID Cap Conference, scheduled for December 7, 2022 at 8:00 a.m. ET. The session will be available via webcast on the company's website and archived for 14 days. Alkermes is focused on developing innovative medicines in neuroscience and oncology, with products targeting alcohol and opioid dependence, schizophrenia, and bipolar disorder. The company operates globally with facilities in Dublin, Massachusetts, Ireland, and Ohio.

Alkermes plc (Nasdaq: ALKS) will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on November 29, 2022, at 2:40 p.m. ET. The event will be accessible through a live webcast on Alkermes’ investor page, with an archived version available for 14 days post-event. Alkermes is a global biopharmaceutical company focused on innovative medicines for neuroscience and oncology, with a diverse portfolio aimed at treating alcohol dependence, opioid dependence, schizophrenia, and bipolar disorder.

Alkermes plc (Nasdaq: ALKS) announced participation in a fireside chat at the Stifel 2022 Healthcare Conference on November 15, 2022, at 8:00 a.m. ET. The live webcast will be accessible on the company's website and archived for 14 days.

Alkermes is a global biopharmaceutical company focused on developing innovative treatments in neuroscience and oncology, with products aimed at alcohol and opioid dependence, schizophrenia, and bipolar disorder.

Alkermes plc (ALKS) reported Q3 2022 revenues of $252.4 million, a decline from $294.1 million year-over-year. Net sales of proprietary products rose to $199.4 million, driven by LYBALVI's launch, achieving $27.1 million. However, GAAP loss per share was $0.39, up from $0.18 a year earlier. The company plans to separate its neuroscience and oncology businesses. Financial guidance for 2022 has been raised, citing LYBALVI's performance and updates on long-acting INVEGA royalties.

Alkermes plc (Nasdaq: ALKS) plans to separate its commercial-stage neuroscience business from its development-stage oncology business to enhance focus, allocate capital effectively, and create distinct investment profiles. This strategic decision is expected to unlock shareholder value by allowing each business to pursue tailored growth strategies. The separation, anticipated in the second half of 2023, will enable Alkermes to concentrate on its neuroscience products while the new Oncology Co. will develop cancer therapies, including the investigational drug nemvaleukin. Financial details will follow.

Acorda Therapeutics reported its Q3 2022 financial results, showing a net revenue increase for both INBRIJA and AMPYRA. INBRIJA U.S. sales reached $7.8 million, up 1% year-over-year, while AMPYRA revenue rose 5% to $21.1 million. The company secured a $16.5 million arbitration award from Alkermes, relieving it from royalty payments on AMPYRA. A special stockholders meeting is scheduled for November 4, 2022, to authorize a reverse stock split to avoid Nasdaq delisting. The 2022 guidance remains unchanged, with projected AMPYRA revenue between $68-78 million.